[A23-58] Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V
Last updated 02.10.2023
Project no.:
A23-58
Commission:
Commission awarded on 30.06.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age and older
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.